A Study to Assess the Safety of Myozyme® and of Aldurazyme® in Male and Female Participants of Any Age Group With Pompe Disease or With Mucopolysaccharidosis Type I (MPS I) in a Home-care Setting

Pompe Disease Clinical Trial

— HomERT  

Official title:

Multi-Centre, Non-Interventional, Double Cohort Study to Assess the Safety of Myozyme® and of Aldurazyme® in Real-World Home Infusion Setting

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05073783
• Other study ID #: OBS17128
• Secondary ID: U1111-1266-7312
• Status: Completed
• Start date: October 14, 2021
• Est. completion date: January 31, 2024

Study information

• Verified date: February 2024
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Primary objective: To obtain data pertaining to the safety and tolerability of alglucosidase alfa and laronidase treatments administered in a home-care infusion setting. Secondary objectives: - To evaluate personal satisfaction of both cohorts of patients treated in a home-care infusion setting. - To evaluate the infusion compliance in both cohorts of patients treated in a home-care infusion setting.

Description:

Prospective observation duration for each patient: at least 12 months (from enrollment)

Recruitment information / eligibility

• Status: Completed
• Enrollment: 57
• Est. completion date: January 31, 2024
• Est. primary completion date: January 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Signed, informed consent obtained prior to being enrolled into the study and prior to starting any data collection. Consent of a legally authorized guardian is required for legally minor patients as defined by local regulation. If the patient is legally minor, signed written consent shall be obtained from parent(s)/legal guardian and assent obtained from the patient, if applicable.
• Pompe disease patients with confirmed acid alpha-glucosidase (GAA) enzyme deficiency treated with Myozyme® in home infusion setting according to authorized clinical practice and the approved risk management plan document (Cohort A) or
• MPS I patients with confirmed deficiency of the lysosomal enzyme, alpha-L-iduronidase treated with Aldurazyme® in home infusion setting according to authorized clinical practice and the approved risk management plan document (Cohort B).

Exclusion Criteria:

• Participation in another clinical trial with any investigational agent within the 12 weeks preceding enrolment.
• Any condition (e.g. medical concern) which, in the opinion of the Investigator, would make the participant unsuitable for the study. The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Related Conditions & MeSH terms

• Glycogen Storage Disease Type II
• Mucopolysaccharidoses
• Mucopolysaccharidosis I
• Mucopolysaccharidosis Type I (MPS I)
• Pompe Disease

Locations

Country	Name	City	State
Italy	Investigational Site Italy	Italy

Sponsors (1)

Lead Sponsor	Collaborator
Sanofi

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with treatment-emergent adverse events (TEAEs)	Treatment emergent adverse events (TEAEs) are defined as any event which are not present prior to the initiation of the Enzyme replacement therapy (ERT) administration in homecare setting or any event already present that worsens in either intensity or frequency following initiation of ERT administration in home-care setting.	For at least 12 months starting from enrollment (day 0)
Primary	Number of participants with treatment-emergent adverse events (TEAEs) for each class of severity	TEAEs are defined as any event which are not present prior to the initiation of the ERT administration in homecare setting or any event already present that worsens in either intensity or frequency following initiation of ERT administration in home-care setting. An adverse event grading scale of mild, moderate and severe is used for grading of adverse event severity.	For at least 12 months starting from enrollment (day 0)
Primary	Number of participants with serious treatment-emergent adverse events (TEAEs)	A serious adverse event (SAE) is any untoward medical occurrence that at any dose: 1) results in death or 2) is life-threatening or 3) requires inpatient hospitalization or prolongation of existing hospitalization or 4) results in persistent or significant disability/incapacity or 5) is a congenital anomaly/birth defect or 6) is a medically important event.	For at least 12 months starting from enrollment (day 0)
Primary	Number of participants with treatment-emergent adverse events (TEAEs) related to alglucosidase or laronidase	TEAEs are defined as any event which are not present prior to the initiation of the ERT administration in homecare setting or any event already present that worsens in either intensity or frequency following initiation of ERT administration in home-care setting. A TEAE is defined as treatment-related if it has a reasonable possibility that the event is related to alglucosidase or laronidase.	For at least 12 months starting from enrollment (day 0)
Primary	Number of participants with infusion associated reactions (IARs)	IARs are defined as AEs that occur during either the infusion or the observation period following the infusion which are deemed to be related or possibly related to Myozyme® and Aldurazyme®. At the discretion of the Investigator, AEs occurring after completion of the post-infusion observation period that are assessed as related may also be considered IARs.	For at least 12 months starting from enrollment (day 0)
Primary	Number of participants with concomitant medications for each Anatomical Therapeutic Chemical (ATC) classification systems	Participants will be asked about their use of concomitant medication at enrollment.	At enrollment (day 0)
Primary	Number of participants with change in the use of concomitant medications in case of non-tolerated infusion	Participants will be asked about their perception regarding any additional medications or treatments or any changes in regimen or dosages compared to their baseline (day 0) state. Any change in the therapy (increased therapy, decrease therapy, no change in therapy) during the study will be reported.	For at least 12 months starting from enrollment (day 0)
Secondary	Patient satisfaction	Patient satisfaction data will be collected through a satisfaction questionnaire, including potential benefits in terms of stress, time and costs. The questionnaire aims to evaluate patient satisfaction about home infusion: 1) where do you prefer to receive ERT, home or hospital; 2) why (list of reasons); 3) how do you feel now; 4) if you are in home infusion, how do you rate your health than when you were treated in hospital.	For at least 12 months starting from enrollment (day 0)
Secondary	Patient compliance	Patient compliance is assessed as number of missed infusions versus planned and/or return to hospital setting (with reasons).	For at least 12 months starting from enrollment (day 0)